$56.64 1.2%
CYTK Stock Price vs. AI Score (Last 150 days)
Data gathered: July 15

AI Score



Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

About Cytokinetics

Cytokinetics, Inc. is a publicly traded biopharmaceutical company based in South San Francisco, California, that develops muscle activators and muscle inhibitors as potential treatments for people with diseases characterized by impaired or declining muscle function.


Cytokinetics
Price $56.64
Target Price Sign up
Volume 124,670
Market Cap $6.56B
Year Range $31.22 - $108.06
Dividend Yield 0%
Revenue per Employee $7,948
Industry Biotechnology

In the news


Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q1 '24046M-52M-136M0-1.330
Q4 '231.7M44M-50M-137M-121M-1.380
Q3 '23380,00040M-47M-129M-115M-1.350
Q2 '23870,00040M-46M-129M-115M-1.340
Q1 '234.6M50M-52M-131M-118M-1.380

Insider Transactions View All

Blum Robert I filed to sell 399,412 shares at $54.3.
July 10 '24
Malik Fady Ibraham filed to sell 131,004 shares at $55.9.
July 9 '24
Malik Fady Ibraham filed to sell 133,004 shares at $55.9.
July 9 '24
Harrington Robert Arthur filed to sell 15,516 shares at $54.6.
July 8 '24
PARSHALL B LYNNE filed to sell 20,600 shares at $54.2.
July 1 '24

What is the Market Cap of Cytokinetics?

The Market Cap of Cytokinetics is $6.56B.

How Many People Work at Cytokinetics?

As of our latest update, Cytokinetics employed approximately 367 people worldwide. However, it's important to note that Cytokinetics' workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.

What is Cytokinetics' revenue per employee?

$7,948. To calculate Cytokinetics' revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.

What is the current stock price of Cytokinetics?

Currently, the price of one share of Cytokinetics stock is $56.64.

How can I analyze the CYTK stock price chart for investment decisions?

The CYTK stock price chart above provides a comprehensive visual representation of Cytokinetics' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Cytokinetics shares. Our platform offers an up-to-date CYTK stock price chart, along with technical data analysis and alternative data insights.

Does CYTK offer dividends to its shareholders?

As of our latest update, Cytokinetics (CYTK) does not offer dividends to its shareholders. Investors interested in Cytokinetics should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of Cytokinetics?

Some of the similar stocks of Cytokinetics are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.

.
The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.